ORIC Pharmaceuticals Inc Stock
ORIC Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $599.82m |
| Enterprise Value | $330.57m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.19 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-134.75m |
| Free Cash Flow (TTM) Free Cash Flow | $-110.30m |
| Cash position | $272.37m |
Is ORIC Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
ORIC Pharmaceuticals Inc Stock Analysis
Analyst Opinions
12 Analysts have issued a ORIC Pharmaceuticals Inc forecast:
Analyst Opinions
12 Analysts have issued a ORIC Pharmaceuticals Inc forecast:
Financial data from ORIC Pharmaceuticals Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -1.07 -1.07 |
5%
5%
|
|
| EBITDA | -134 -134 |
33%
33%
|
EBIT (Operating Income) EBIT | -135 -135 |
33%
33%
|
| Net Profit | -120 -120 |
29%
29%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about ORIC Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ORIC Pharmaceuticals Inc Stock News
Company Profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
| Head office | United States |
| CEO | Jacob Chacko |
| Employees | 100 |
| Founded | 2014 |
| Website | www.oricpharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
